Medical school admissions after the Supreme Court’s 2023 Affirmative Action ruling
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Dec-2025 11:11 ET (28-Dec-2025 16:11 GMT/UTC)
The newly launched EASYGEN (Easy workflow integration for gene therapy) consortium will develop a fully automated, hospital-based platform capable of manufacturing personalised cell therapies within a few days. Fresenius SE & Co. KGaA is leading this €8 million EU-backed effort to make CAR-T cell therapy faster, more affordable, and more accessible to patients across Europe. As one of the eighteen consortium partners, EBMT will participate in a study examining current CAR-T treatment processes. EBMT will conduct a literature review on the quality of life of patients treated under existing CAR-T delivery models and will also contribute to patient education and advocacy efforts.
Where are the children with disabilities? It’s not kids’ picture books, according to new research from Edith Cowan University’s (ECU) School of Education.